Resources - COVID-19 information

Section dedicated to information on pharmacovigilance of medicinal products used to treat and prevent COVID-19 (coronavirus).

The section is divided into two parts: one part relating to links to national and international institutional websites on SARS-CoV-2 (COVID-19) and another part relating to research documents by the North American chapter (NASoP) and the Italian Society of Pharmacology (SIF).
This page will be regularly updated.

COVID-19 Resources

Here you will find some links to national and international institutional websites and published papers on COVID-19. Stay informed with the latest clinical research and resources.

World Health Organisation

Centers for Disease Control and Prevention

CUS National Institute of Health about the COVID-19 therapeutic options under investigation

European Medicines Agency

COVID-19 data sources (Knowledge Portal on Innovation and Access to Medicines)

The Lancet

The New England Journal Of Medicine

Oxford Covid-19 Evidence service

The Royal College of Obstetricians and Gynaecologists (RCOG)

Italian Society of Pharmacology - English COVID-19 section

JAMA Network

International Union of Pharmacology and Clinical Pharmacology (IUPHAR)

NIPH-Live map of COVID-19 evidence

Springer Nature

Position Papers and initiatives

ISoP colleagues in the North American Chapter of ISoP (NASoP) and the Italian Society of Pharmacology (SIF) are working on proposals to monitor the safety of medicines and vaccines to treat and prevent COVID-19.

Official statement of the section of Clinical Pharmacology of the Italian Society of Pharmacology on the use of ACE- inhibitors or angiotensin receptor blockers in COVID-19 infection with commentary

SIF

Official Statement of the section of Clinical Pharmacology of Italian Society of Pharmacology on Non-steroidal anti-inflammatory drugs (NSAIDs) and the increased risk of complications during infections with commentary

SIF

Simplified description of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Viral lifecycle and drug repurposing strategies

Disclaimer
The contents of this page are intended for purely informational purposes (the list is not exhaustive).
May 2020